Get to know our clinical trials

Assay of MCLA-128, a bispecific, full-length IgG1 antibody specifically targeting HER2 and HER3 in patients with solid tumors

THE MAIN GOAL OF THIS TRIAL IS TO TEST THE SAFETY OF THE MCLA-128 TRIAL DRUG IN PATIENTS WITH SOLID (EPITHELIAL-TYPE) TUMORS LIKE YOURS AND TO SEE WHAT EFFECTS IT HAS ON PATIENTS AND THEIR CANCER.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE I/II STUDY OF MCLA-128, A BISPECIFIC, COMPREHENSIVE IGG1 ANTIBODY SPECIFICALLY TARGETING HER2 AND HER3 IN PATIENTS WITH SOLID TUMORS
  • Code EudraCT: 2014-003277-42
  • Protocol number: MCLA-128-CL01
  • Promoter: Merus N.V.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.